URC
URIC ACID
| Created: | 2002-03-15 |
| Last modified: | 2021-03-13 |
Find Related PDB Entry |
|---|
Find related ligands: |
|---|
Chemical Details | |
|---|---|
| Formal Charge | 0 |
| Atom Count | 16 |
| Chiral Atom Count | 0 |
| Bond Count | 17 |
| Aromatic Bond Count | 10 |
Chemical Component Summary | |
|---|---|
| Name | URIC ACID |
| Synonyms | 7,9-DIHYDRO-1H-PURINE-2,6,8(3H)-TRIONE |
| Systematic Name (OpenEye OEToolkits) | 7,9-dihydro-3H-purine-2,6,8-trione |
| Formula | C5 H4 N4 O3 |
| Molecular Weight | 168.11 |
| Type | NON-POLYMER |
Chemical Descriptors | |||
|---|---|---|---|
| Type | Program | Version | Descriptor |
| SMILES | ACDLabs | 10.04 | O=C1C2=C(NC(=O)N1)NC(=O)N2 |
| SMILES | CACTVS | 3.341 | O=C1NC(=O)C2=C(N1)NC(=O)N2 |
| SMILES | OpenEye OEToolkits | 1.5.0 | C12=C(NC(=O)N1)NC(=O)NC2=O |
| Canonical SMILES | CACTVS | 3.341 | O=C1NC(=O)C2=C(N1)NC(=O)N2 |
| Canonical SMILES | OpenEye OEToolkits | 1.5.0 | C12=C(NC(=O)N1)NC(=O)NC2=O |
| InChI | InChI | 1.03 | InChI=1S/C5H4N4O3/c10-3-1-2(7-4(11)6-1)8-5(12)9-3/h(H4,6,7,8,9,10,11,12) |
| InChIKey | InChI | 1.03 | LEHOTFFKMJEONL-UHFFFAOYSA-N |
Drug Info: DrugBank
| DrugBank ID | DB08844 |
|---|---|
| Name | Uric acid |
| Groups | investigational |
| Description | Uric acid is the last product of purine metabolism in humans. The formation of uric acid is through the enzyme xanthine oxidase, which oxidizes oxypurines. Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. At present (August 2013), there is no approved formulation or indication for uric acid. In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke. |
| Synonyms |
|
| Indication | At present (August 2013), there is no approved indication for uric acid. The potential therapeutic use for uric acid is as an adjunct in acute ischemic stroke. |
| Categories |
|
| CAS number | 69-93-2 |
Drug Targets
| Name | Target Sequence | Pharmacological Action | Actions |
|---|---|---|---|
| Glycogen phosphorylase, liver form | - | unknown | |
| Solute carrier family 22 member 6 | MAFNDLLQQVGGVGRFQQIQVTLVVLPLLLMASHNTLQNFTAAIPTHHCR... | unknown | |
| Solute carrier family 22 member 8 | MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR... | unknown | |
| Solute carrier family 2, facilitated glucose transporter member 9 | MARKQNRNSKELGLVPLTDDTSHAGPPGPGRALLECDHLRSGVPGGRRRK... | unknown | substrate |
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
Related Resource References
| Resource Name | Reference |
|---|---|
| PubChem | 1175, 5274273 |
| ChEMBL | CHEMBL792 |
| ChEBI | CHEBI:17775, CHEBI:46811, CHEBI:46814, CHEBI:62589, CHEBI:46817, CHEBI:46823 |
| CCDC/CSD | URICAC, URICAC06, URICAC05, URICAC04, URICAC03, URICAC02, GADGIF, URICAC01 |
